2025 Global Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report
Description
The 2025 Global Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Amyotrophic Lateral Sclerosis (ALS) treatment market are Mitsubishi Tanabe Pharma Corporation, Biogen Inc., Sanofi S.A., and BrainStorm Cell Therapeutics Inc. Mitsubishi Tanabe Pharma, part of Mitsubishi Chemical Group, is a key player with a strong presence in ALS drug development and clinical trials. Biogen is notable for its innovative therapies, including QALSODY, the first therapy targeting the genetic cause of SOD1-ALS, holding FDA approval. Sanofi contributes significantly with its product Rilutek (riluzole) and extensive research collaborations globally, while BrainStorm Cell is distinguished for pioneering cell therapies in ALS treatment.
These companies dominate due to their substantial investment in research and development, fostering innovation in treatments ranging from disease-modifying drugs to cell and gene therapies. Mitsubishi Tanabe Pharma and Biogen lead in genetic and targeted intervention therapies, while Sanofi’s global reach supports broad clinical trial networks and drug availability. BrainStorm’s focus on regenerative cell therapy and Amylyx Pharmaceuticals' novel therapies also mark critical advances in ALS care. Their efforts align with increasing awareness, supportive regulatory frameworks, and growing healthcare infrastructure across North America, Europe, and Asia-Pacific regions, positioning them at the forefront of ALS therapeutic advancements worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Amyotrophic Lateral Sclerosis (ALS) treatment market are Mitsubishi Tanabe Pharma Corporation, Biogen Inc., Sanofi S.A., and BrainStorm Cell Therapeutics Inc. Mitsubishi Tanabe Pharma, part of Mitsubishi Chemical Group, is a key player with a strong presence in ALS drug development and clinical trials. Biogen is notable for its innovative therapies, including QALSODY, the first therapy targeting the genetic cause of SOD1-ALS, holding FDA approval. Sanofi contributes significantly with its product Rilutek (riluzole) and extensive research collaborations globally, while BrainStorm Cell is distinguished for pioneering cell therapies in ALS treatment.
These companies dominate due to their substantial investment in research and development, fostering innovation in treatments ranging from disease-modifying drugs to cell and gene therapies. Mitsubishi Tanabe Pharma and Biogen lead in genetic and targeted intervention therapies, while Sanofi’s global reach supports broad clinical trial networks and drug availability. BrainStorm’s focus on regenerative cell therapy and Amylyx Pharmaceuticals' novel therapies also mark critical advances in ALS care. Their efforts align with increasing awareness, supportive regulatory frameworks, and growing healthcare infrastructure across North America, Europe, and Asia-Pacific regions, positioning them at the forefront of ALS therapeutic advancements worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
